ArticleMetabolic brain disease2025
ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (St3gal4) deficiency reveals correlations among alkaline phosphatase activity, metabolic parameters, and fear-related behavior in mice.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Biomarkers Associated With Copper Metabolism in Ischemic Stroke Through Bulk RNA Sequencing and Mendelian Randomization Analysis.Cellular and molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (ST3GAL4) is a sialyltransferase involved in the biosynthesis of alpha2,3-sialic acid on glycoproteins and glycolipids. In mice, St3gal4 gene expression plays a crucial role in modulating epilepsy and anxiety/depression through its expression in thalamic neurons. Genome-wide association studies (GWAS) have identified several peripheral metabolic traits strongly associated with ST3GAL4 in humans. However, whether the symptoms observed in mice are associated with metabolic changes remains unclear. This study investigated the effects of St3gal4 deficiency on the same metabolic parameters in mice as those in humans. The parameters examined included body weight, plasma biochemistry, specifically alkaline phosphatase (ALP), protein, and cholesterol levels, and free amino acids profiles, resulting in elevated ALP and reduced tryptophan and total cholesterol (T-Cho) levels in St3gal4-knockout (KO) mice. Additionally, clearance of blood glucose was delayed in KO male mice. These findings suggest mouse St3gal4 deficiency correlated with modulated ALP, tryptophan, and T-Cho levels in the plasma. Next, brain ALP activity was compared between St3gal4-KO mice and wild-type (WT) mice, focusing on the thalamus. Fear conditioning tests assessed the relationship between behavior and ALP activity in plasma and brain. In KO mice, the enhanced tone freezing positively correlated with plasma ALP levels. Conversely, thalamic ALP activity was greatly reduced in KO mice, negatively correlating with plasma ALP. These findings suggest that mouse St3gal4 deficiency influences ALP activity in both thalamus and plasma, associating with emotional behaviors and metabolic changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.